CeleCor Therapeutics

Developing, RUC-4, a novel  small molecule inhibitor of the platelet αIIbβ3 receptor, designed to be easily administered subcutaneously by auto-injector to facilitate its use as the  first point of contact treatment for STEMI

Focus area
Other
Commencement date
05/16/2017